
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots
New data presented at the American College of Cardiology 2025 Scientific Session demonstrate that at 3 months of follow-up, patients hospitalized for a serious heart attack who were treated with rivaroxaban (Xarelto; Johnson & Johnson) for a blood clot …